Ideas
Intel turnaround faces supply and yield setbacks
Intel's weak forecast reflects a supply problem: low manufacturing yields mean it cannot fulfill orders, which is unexpected and a troubling sign the turnaround could be harder than investors hoped. Intel also lags AMD and Qualcomm and missed the AI boom, so it must show momentum.
AI demand still fuels Asian suppliers
The AI narrative remains in place and is helping fuel demand for Korean, Japanese, and Chinese companies, which have been diverging even during turbulence in U.S. markets. Investors are still focused on how much further the AI story can run.
Chip IPO fuels Alibaba AI narrative
Alibaba's T-Head chip-unit IPO continues to fuel the existing AI narrative and is good for investors while it lasts, but it is a much smaller offering than a potential OpenAI IPO and may gradually erode market funds. Investors must decide whether to stay with existing AI companies or shift to newer ones.
BOJ may pause taper to aid JGBs
The BOJ is not expected to change rates, but the governor's press conference is key. Disruptions in the long end of the JGB market are concerning; the BOJ may need to pause its bond-purchase reductions to stabilize the market, which would be a boost.
Tesla Optimus robot sales approaching
Tesla is preparing for commercial release of its Optimus robots, already using them for simple factory tasks, and Musk expects to sell humanoid robots to the public by the end of 2026 once reliability, safety, and functionality are high.
AI capex is not a bubble
Fink sees no AI bubble: hundreds of billions of dollars of capex are needed and will drive global growth, with opportunities in data centers, grids, and new power sources. BlackRock is raising money, acquired data centers, and partners with Microsoft, NVIDIA, and MDX in Abu Dhabi.
China biotech trials and deals growing
China's clinical trial registrations have surged from about 5% to one third of global trials, helped by government innovation support, population scale, and cost efficiency. M&A and licensing deal value has reached roughly $100 billion, creating a large opportunity set.
Sino Bio pipeline and licensing offer growth
Sino Biopharmaceuticals will stay focused on oncology, hepatitis, surgery, and respiratory areas while exploring cardiovascular and metabolism. It has good molecules attracting big pharma interest and expects M&A, licensing, and partnership opportunities to drive growth.
Global equities still offer medium-term upside
Qiao remains bullish on global equities and sees further upside, especially medium-term, despite the recent surge. Diversifying across Japan, emerging markets, Europe, and China can help investors navigate short-term volatility.
Yen appreciation drives USD/JPY lower
Qiao expects USD/JPY to trend lower over the next 12 months from yen appreciation, following the recent rise in the 10-year JGB yield. Short-term volatility should remain elevated, but yields may decline in February.
Korea neutral on memory, political risks
Qiao maintains a neutral stance on South Korea because of its reliance on memory chips and political and tariff risks. The firm would rather focus tech exposure on the U.S. and China.
Chinese tech equities have upside
Chinese technology equities have substantial upside and have seen a strong bounceback, especially in Hong Kong markets. The overall Chinese economy is improving, though some political tensions still need to be resolved.
AI infrastructure overinvestment risks warrant caution
Qiao is cautious on artificial intelligence investments because of potential inflation spikes, corporate earnings risk, and overinvestment in AI infrastructure. The firm still wants tech exposure but is diversifying away from concentrated tech risk.
Rotate beyond tech into materials, industrials, energy
The market rotation is broadening beyond tech: materials, industrials, and energy are up 7% to 9% this year in line with growth. Qiao wants to broaden exposure beyond tech into these sectors.
Central banks buy gold, supporting prices
Dalio says the world is moving toward a capital war amid reserve shifts and geopolitical tensions. Central banks are buying gold and replacing bonds and other assets, which supports gold as a diversification asset.
Investors diversify away from U.S. markets
Dalio says investors are diversifying away from U.S. assets. U.S. markets put in wonderful performance last year but underperformed the rest of the world, and there is a shift in the assets held.
This Bloomberg Markets video, published January 23, 2026,
features Sarah Frier, Mark Cranfield, Elon Musk, Larry Fink, Eric Tse, Xi Qiao, Ray Dalio
discussing INTC, AI-SECTOR, BABA, Japanese government bonds, TSLA, AIQ, DTCR, KURE, 1177.HK, VT, USD/JPY, EWY, CQQQ, XLB, XLI, XLE, GLD, ACWX.
16 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Sarah Frier,
Mark Cranfield,
Elon Musk,
Larry Fink,
Eric Tse,
Xi Qiao,
Ray Dalio
· Tickers:
INTC,
AI-SECTOR,
BABA,
Japanese government bonds,
TSLA,
AIQ,
DTCR,
KURE,
1177.HK,
VT,
USD/JPY,
EWY,
CQQQ,
XLB,
XLI,
XLE,
GLD,
ACWX
